Can the extent of heart rate reduction predict the clinical response of infantile haemangiomas to propranolol?

Chong, Jin Ho; Prey, S.; Mya, Hae Tha; Delarue, Alain; Labrèze, Christine

doi:10.1111/bjd.15966

Cited by 4 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chong and colleagues recognized that there is no relationship between the extent of heart rate (HR) decline after propranolol administration and clinical response 6 months after propranolol therapy. [15] Furthermore, some scholars assumed that the initial response to propranolol could predict the final outcome of IHs. [8] Although the significant effect of propranolol on IHs has been conformed, [16] the number of partial responders and non-responders has also been growing.…”

Section: Discussionmentioning

confidence: 99%

“…A large study of include 101 individuals showed that three were poor responders and 39 were moderate responders at 6 months after propranolol therapy. [15] A retrospective study [17] revealed that excellent response rates were achieved in 65.4% of infants mean 6.5 months after treatment initiation. In our study, the clinical good response rate was 67.07% at 6 months after treatment and 83.63% at the end of treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol

Guo²,

Wang³

et al. 2019

Medicine

View full text Add to dashboard Cite

Propranolol is the mainstay of treatment for infantile hemangiomas (IHs) benefited from its low complication in the present study. However, it has an uncertainty treating period with cumbersome methods which may be related to clinical features. This study sought to considered possible influences of short-term efficacy to medication. Retrospective analysis of 82 patients with IHs treated by propranolol was performed. The patients were grouped according to effect (excellent, good and fair/poor). ANOVA or t test was used to assess the relationships between effect and clinical features of IHs. Twenty-seven patients were males and 55 were females. The median age of treatment initiation was 3.5 (±2.11) months. Mean follow-up time for the group was 6.2 months (1.5–16 months). There were no significant associations between short-term efficacy and gender, time points of treatment, diameter of tumor and multifocality. However, tumor thickness was associated with short-term efficacy ( P = .013). Moreover, an obvious difference of short-term efficacy has been found when tumor thickness <1.2 cm. In the present study, tumor thickness was associated with the short-term efficacy in patients with IHs. Propranolol may be gets a better outcome when tumor thickness <1.2 cm at a short time.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol

Guo²,

Wang³

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…A study tried to find the correlation between heart rate reduction after propranolol administration and the clinical outcome of propranolol therapy for IH. But no relationship was proved after six months of propranolol therapy [10].…”

Section: Introductionmentioning

confidence: 97%

Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma

Wang

Zheng

Xin-lin

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Objective. The aim of this study is to evaluate the association of genetic polymorphisms in Cytochrome P450 2D6(CYP2D6) and the change in VEGF levels with the response to propranolol in patients with Infantile hemangiomas (IH). Methods. IH patients who underwent over six months of propranolol therapy and received oral propranolol only were enrolled. The target dose of propranolol was 1 mg kg−1day−1. Deoxyribonucleic acid was obtained from venous blood leukocytes. Genotypes of CYP2D6 (rs1065852 and rs1135840) were tested by polymerase chain reaction (PCR) and by sequencing the products. Baseline serum VEGF and serum VEGF one month after treatment were measured. The clinical responses after six months of treatment were evaluated. Genotypes of CYP2D6 (rs1065852 and rs1135840) and VEGF levels were compared between good responders and poor-to-moderate responders. Results. 72 patients were enrolled in the study. Patients with CYP2D6 (rs1135840) G/G homozygote had the highest response rate to propranolol. No significant association was found between the response rates and CYP2D6 (rs1065852) polymorphism. No significant differences were found in baseline serum VEGF, serum VEGF one month after treatment, and VEGF ratio between good responders and poor-to-moderate responders. Conclusion. The response to propranolol treatment in IH patients was associated with the gene polymorphism of CYP2D6 (rs1135840). A low-dose propranolol regimen was effective and safe in young infants with IH. The change of serum VEGF levels after one month’s treatment could not be used to predict the response rate to propranolol.

show abstract

Effects of laser irradiation on growth factors and cell apoptosis of in vitro cultured infant hemangioma endothelial cells

2019

View full text Add to dashboard Cite

Can the extent of heart rate reduction predict the clinical response of infantile haemangiomas to propranolol?

Cited by 4 publications

References 7 publications

Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol

Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol

Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma

Effects of laser irradiation on growth factors and cell apoptosis of in vitro cultured infant hemangioma endothelial cells

Contact Info

Product

Resources

About